At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 167 enrolled
Drug / intervention
DFN-02drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
DFN-02 Open Label Safety Study in Patients With Acute Migraine
In Brief
A Phase 3 clinical trial evaluating DFN-02 for Acute Migraine. Completed, enrolled 167 participants across 24 sites.
Detailed Summary
A multi-center, open-label, safety study of DFN-02 for the Treatment of Acute Migraines
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Migraine
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartSep 2014
First PostedOct 2014
Primary CompletionSep 2015
Study CompletionMar 2016
TodayJul 2026
First PostedOct 30, 2014
Enrollment StartSep 1, 2014
Primary CompletionSep 1, 2015
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 11.7 years ago
Interventions
DFN-02drug
Active Experimental Drug